This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Jun;7(6):e374-e375.

doi: 10.1016/S2352-3018(20)30115-6.

Weighing considerations with newer antiretrovirals

W D Francois Venter¹, Andrew Hill²

Affiliations

Affiliations

¹ Ezintsha, University of the Witwatersrand, Johannesburg 2193, South Africa. Electronic address: fventer@wrhi.ac.za.
² Department of Translational Medicine, University of Liverpool, Liverpool, UK.

PMID: 32504568
DOI: 10.1016/S2352-3018(20)30115-6

Comment

Weighing considerations with newer antiretrovirals

W D Francois Venter et al. Lancet HIV. 2020 Jun.

. 2020 Jun;7(6):e374-e375.

doi: 10.1016/S2352-3018(20)30115-6.

Authors

W D Francois Venter¹, Andrew Hill²

Affiliations

¹ Ezintsha, University of the Witwatersrand, Johannesburg 2193, South Africa. Electronic address: fventer@wrhi.ac.za.
² Department of Translational Medicine, University of Liverpool, Liverpool, UK.

PMID: 32504568
DOI: 10.1016/S2352-3018(20)30115-6

No abstract available

PubMed Disclaimer

Comment on

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.

Similar articles

Bictegravir and dolutegravir: head to head at 96 weeks.
Barber TJ. Barber TJ. Lancet HIV. 2019 Jun;6(6):e342-e343. doi: 10.1016/S2352-3018(19)30135-3. Epub 2019 May 5. Lancet HIV. 2019. PMID: 31068271 No abstract available.
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Sax PE, et al. Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15. Lancet HIV. 2017. PMID: 28219610 Clinical Trial.
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Orkin C, et al. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. Lancet HIV. 2020. PMID: 32504574 Clinical Trial.
Bictegravir.
Spagnuolo V, Castagna A, Lazzarin A. Spagnuolo V, et al. Curr Opin HIV AIDS. 2018 Jul;13(4):326-333. doi: 10.1097/COH.0000000000000468. Curr Opin HIV AIDS. 2018. PMID: 29746268 Review.
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
Maartens G, Boffito M, Flexner CW. Maartens G, et al. Curr Opin HIV AIDS. 2017 Jul;12(4):355-358. doi: 10.1097/COH.0000000000000376. Curr Opin HIV AIDS. 2017. PMID: 28403028 Review.

See all similar articles

Cited by

Adolescents' understanding of obesity: a qualitative study from rural South Africa.
Seabi TM, Wagner RG, Norris SA, Tollman SM, Twine R, Dunger DB, Kahn K. Seabi TM, et al. Glob Health Action. 2021 Jan 1;14(1):1968598. doi: 10.1080/16549716.2021.1968598. Glob Health Action. 2021. PMID: 34482795 Free PMC article.
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).
Podzamczer D, Micán R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masiá M, Gómez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro Á, Bernal E, Vinuesa D, Knobel H, Troya J, Macías J, Montero M, Sanz J, Navarro-Alcaraz A, Caicedo A, Fernández G, Martínez E, Moreno S. Podzamczer D, et al. Open Forum Infect Dis. 2021 Nov 25;9(3):ofab595. doi: 10.1093/ofid/ofab595. eCollection 2022 Mar. Open Forum Infect Dis. 2021. PMID: 35237700 Free PMC article.
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D²EFT): an open-label, randomised, phase 3b/4 trial.
D2EFT Study Group. D2EFT Study Group. Lancet HIV. 2024 Jul;11(7):e436-e448. doi: 10.1016/S2352-3018(24)00089-4. Epub 2024 May 21. Lancet HIV. 2024. PMID: 38788744 Free PMC article. Clinical Trial.
Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda.
Guaraldi G, Bonfanti P, Di Biagio A, Gori A, Milić J, Saltini P, Segala FV, Squillace N, Taramasso L, Cingolani A. Guaraldi G, et al. BMC Infect Dis. 2023 Apr 14;23(1):230. doi: 10.1186/s12879-023-08174-3. BMC Infect Dis. 2023. PMID: 37060030 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information